0001104659-23-091942.txt : 20230815 0001104659-23-091942.hdr.sgml : 20230815 20230815160213 ACCESSION NUMBER: 0001104659-23-091942 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230815 DATE AS OF CHANGE: 20230815 EFFECTIVENESS DATE: 20230815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-489816 FILM NUMBER: 231174828 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 D 1 primary_doc.xml X0708 D LIVE 0001420720 iBio, Inc. 8800 HSC PARKWAY BRYAN TX TEXAS 77807 (979) 446-0027 DELAWARE None iBioPharma, Inc. InB:Biotechnologies, Inc. Corporation true Martin Brenner 8800 HSC Parkway Bryan TX TEXAS 77807 Executive Officer Felipe Duran 8800 HSC Parkway Bryan TX TEXAS 77807 Executive Officer Marc Banjak 8800 HSC Parkway Bryan TX TEXAS 77807 Executive Officer Linda Armstrong 8800 HSC Parkway Bryan TX TEXAS 77807 Director Alexandra Kropotova 8800 HSC Parkway Bryan TX TEXAS 77807 Director William Clark 8800 HSC Parkway Bryan TX TEXAS 77807 Director Gary Sender 8800 HSC Parkway Bryan TX TEXAS 77807 Director James Hill 8800 HSC Parkway Bryan TX TEXAS 77807 Director Evert Schimmelpennink 8800 HSC Parkway Bryan TX TEXAS 77807 Director Biotechnology Decline to Disclose 06b false 2023-08-04 false true false 0 10000000 0 10000000 211,473 shares were issued as a commitment fee false 1 0 0 0 true While no offering proceeds are set aside for payments to named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers. false iBio, Inc. /s/ Felipe Duran Felipe Duran Chief Financial Officer 2023-08-15